Takeda Pharmaceutical (TKPHF) Cash & Current Investments (2017 - 2026)

Takeda Pharmaceutical's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $6.6 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 36.76% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 36.76% YoY), while the FY2026 annual figure was $6.9 billion, up 42.26% from the prior year.
• Cash & Current Investments was $6.6 billion for Q1 2026 at Takeda Pharmaceutical, down from $7.0 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $8.8 billion in Q2 2022 to a low of $3.2 billion in Q1 2024.
• Historically, Cash & Current Investments has averaged $6.1 billion across 5 years, with a median of $5.9 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments tumbled 44.4% in 2023, then jumped 51.23% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $8.0 billion in 2022, then sank by 31.75% to $5.4 billion in 2023, then grew by 3.55% to $5.6 billion in 2024, then rose by 24.61% to $7.0 billion in 2025, then retreated by 5.86% to $6.6 billion in 2026.
• The last three Cash & Current Investments figures came in at $6.6 billion (Q1 2026), $7.0 billion (Q4 2025), and $7.1 billion (Q3 2025), per Business Quant data.